![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
H Saitoh, C Gerard and BJ Aungst
Du Pont Merck Research Laboratories, Wilmington, Delaware, USA.
The mechanisms of intestinal permeation of several beta-lactam antibiotics and anionic compounds were studied in vitro using excised rat intestinal segments. Permeation of cefazolin through jejunum, ileum and colon was highly secretory-oriented; serosal-to-mucosal permeation rates were two- to three-fold greater than mucosal-to-serosal permeation rates. Serosal-to-mucosal permeation decreased in the absence of D-glucose, and mucosal-to-serosal permeation increased, indicating that the preferential secretory transport of cefazolin is energy dependent. Ampicillin permeation across rat jejunum also favored secretion, whereas the permeation of cefaclor and cephradine favored absorption. Because cefazolin is anionic, several structurally unrelated anionic compounds were also tested. Of these only phenol red exhibited preferential serosal-to-mucosal permeation. The intestinal permeation of phenol red was concentration dependent and glucose dependent. Verapamil and a monoclonal antibody to P-glycoprotein only modestly and inconsistently affected the permeation of cefazolin, ampicillin and phenol red. Probenecid and guanidine were much more effective inhibitors of cefazolin and phenol red secretion. Mutual interactions between cefazolin and phenol red were also observed. These results show that the rat intestine has the capability for net secretory transport of some hydrophilic, anionic compounds. Transport of these compounds has some of the characteristics of organic anion and organic cation transport systems.
This article has been cited by other articles:
|
|
 |
|
  K. S. Pang MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES) Drug Metab. Dispos., December 1, 2003; 31(12): 1507 - 1519. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lee, C. Ng, K. L. R. Brouwer, and D. R. Thakker Secretory Transport of Ranitidine and Famotidine across Caco-2 Cell Monolayers J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 574 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Naruhashi, I. Tamai, N. Inoue, H. Muraoka, Y. Sai, N. Suzuki, and A. Tsuji Involvement of Multidrug Resistance-Associated Protein 2 in Intestinal Secretion of Grepafloxacin in Rats Antimicrob. Agents Chemother., February 1, 2002; 46(2): 344 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Okudaira, I. Komiya, and Y. Sugiyama Polarized Efflux of Mono- and Diacid Metabolites of ME3229, an Ester-Type Prodrug of a Glycoprotein IIb/IIIa Receptor Antagonist, in Rat Small Intestine J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 717 - 723. [Abstract] [Full Text]
|
|
|
|
|
|
N. Okudaira, T. Tatebayashi, G. C. Speirs, I. Komiya, and Y. Sugiyama A Study of the Intestinal Absorption of an Ester-Type Prodrug, ME3229, in Rats: Active Efflux Transport as a Cause of Poor Bioavailability of the Active Drug J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 580 - 587. [Abstract] [Full Text]
|
|
|
|
|
|
M. T. Skowronski, Y. Ishikawa, and H. Ishida Enhancement by Epinephrine of Benzylpenicillin Transport in Rat Small Intestine J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 128 - 135. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Gotoh, H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama Involvement of an Organic Anion Transporter (Canalicular Multispecific Organic Anion Transporter/Multidrug Resistance-Associated Protein 2) in Gastrointestinal Secretion of Glutathione Conjugates in Rats J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 433 - 439. [Abstract] [Full Text]
|
|
|
|
|
|
A. Collett, N. B. Higgs, E. Sims, M. Rowl, and a. G. Warhurst Modulation of the Permeability of H2 Receptor Antagonists Cimetidine and Ranitidine by P-Glycoprotein in Rat Intestine and the Human Colonic Cell Line Caco-2 J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 171 - 178. [Abstract] [Full Text]
|
|
|
|
|
|
T. Prueksaritanont, P. DeLuna, L. M. Gorham, B. Ma, D. Cohn, J. Pang, X. Xu, K. Leung, and J. H. Lin In Vitro and In Vivo Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and Its Carboxyl Ester Prodrug L-775,318. Roles of Efflux and Metabolism Drug Metab. Dispos., June 1, 1998; 26(6): 520 - 527. [Abstract] [Full Text]
|
|
|
|
|
|
I. Tamai, A. Saheki, R. Saitoh, Y. Sai, I. Yamada, and A. Tsuji Nonlinear Intestinal Absorption of 5-Hydroxytryptamine Receptor Antagonist Caused by Absorptive and Secretory Transporters J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 108 - 115. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
